| |
POSTER
Risk factors for loss
of virological suppression at 48 weeks in patients receiving
lopinavir/ritonavir monotherapy in the OK clinical trial.
F Pulido et al
PDF Poster
|
POSTER
Significantly Reduced Food Effect and
Pharmacokinetic Variability with a Novel
Lopinavir/ritonavir Tablet Formulation
W Awni,et al
PDF Poster
POSTER
Immunologic Reconstitution Through 6 Years in Antiretroviral-Naïve
Subjects
Treated
with Lopinavir/ritonavir (LPV/r)
A Landay,, et al
PDF Poster
POSTER
Once-Daily vs Twice-Daily Lopinavir/ritonavir in
Antiretroviral-Naïve Patients: 96-
Week Results
JM Molina, et al
PDF Poster
Pharmacodynamics of lopinavir in a cohort of 84
HIV infected patients
Wateba M., Billaud E., Dailly E., Raffi F.
Abstract
Significantly reduced food effect and pharmacokinetic
variability with a novel
lopinavir/ritonavir tablet formulation
Awni W, Chiu Y-L, Zhu T.
Abstract
|
Safety of Lopinavir Pharmacokinetics in Combination with Efavirenz
or
Nevirapine in a Nuke-free regimen
Langmann P., Trein A., Zilly M.,
Abstract
|
The
impact of co-infection with Hepatitis C or Hepatitis B on lopinavir
pharmacokinetics in patients infected with HIV
Dickinson L., Micheli V., Meraviglia P., et al
Abstract
|
|
Comparative Analysis of the Clinical, Immunological and Virological
Outcomes of Initial HAART based on Efavirenz or Ritonavir/Lopinavir
in the Clinical Setting.
Moreno A., Perez-Elias M.J., Lopez D., et al
Abstract
Randomized trial of lopinavir versus efavirenz
containing HAART
combinations for post-exposure prophylaxis (PEP) following high-risk
sexual activity
Torres R, Kassous J., Young T., Patterson J.
Abstract
Hepatotoxicity of Lopinavir/ritonavir (LPV/r)
based regimens in patients attending a
HIV/Hepatitis C/B co-infection clinic in Miami
Moreno J., Zambrano J., Jayaweera D, et al
Abstract
|
Development of De Novo PI-Resistance in
Lopinavir/Ritonavir-Monotherapy
Wolf E, Walter H, Eckerlein B, et al
Abstract
Effect of
Lopinavir (LPV) and Atazanavir (ATV) on Proteasome Activity
of Jurkat,
U937 and HEL299 cell lines.
Tronconi E, Groettrup M, Valerio A, et al
Abstract
Outcomes of previously
antiretroviral-naïve patients receiving Kaletra in a
single
treatment centre
Smith C., Phillips A., Sabin C., et al
Abstract
Beneficial Effects of a Switch to a
Lopinavir/r (LPV/r)-Containing Regimen for Patients
with Partial or No Immune Reconstitution with HAART Despite Complete Viral
Suppression.
Pitrak D., Estes R., Tschampa J., et
al
Abstract
|
Early Safety, Tolerability, Efficacy
and Pharmacokinetics of Once Daily (QD)
Lopinavir/Ritonavir (LPV/r) + Tenofovir (TDF) +
Lamivudine (3TC) Among HIV-Infected
African-American Men and Women Naïve to HIV Therapy
– The AAQD Study
Wohl D., Menezes P., Torres R., et al
Abstract
|
|
Therapeutic Drug Monitoring of
Lopinavir/ritonavir (LPV/r) Containing Regimen in
Pregnant HIV-infected Women.
Cassard B, Rouault A, Damond F, et al
Abstract
Pharmacokinetics and 24 week safety
and efficacy of Lopinavir/ritonavir (LPV/r) BID
or QD as part of ART regimen in naïve children
Rosso R., Di Biagio A., Dentone C, et
al
Abstract |
|
|
|
|
|
|
|
|
